PE-22-28
Spadin analog
PRECLINICAL · SPADIN-DERIVED PEPTIDE; TREK-1 CHANNEL BLOCKER
▓ 3 indexed citations across PubMed (1), EuropePMC (2).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
TREK-1 potassium channel inhibition; enhances serotonergic transmission; neurogenesis
Researched effects
TREK-1 inhibition; antidepressant effect; neurogenesis
Live evidence
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
200-500 mcg SC daily (research)
Known concerns
Very limited human data
Top-ranked picks
3 pre-curated authoritative sources, ranked by journal tier and study weight.
Full citation library
Year distribution
No references match — clear filters.
Research Articles
3-
1.
Depression is a devastating mental disorder that affects 20% of the population worldwide. Despite their proven efficacy, antidepressants present a delayed onset of action and serious adverse effects. Seven years ago, we described spadin (PE 12-28) as a promising endogenous peptide with antidepressant activity. Spadin specifically blocks the TREK-1 channel. Previously, we showed
-
2.
<h4>Rationale</h4>Although depression is the most common mood disorder, only one third of patients are treated with success. Finding new targets, new drugs, and also new drug intake way are the main challenges in the depression field. Several years ago, we identified a new target with the TWIK-related potassium channel-1 (TREK-1) potassium channel, and more recently, we have discovered a peptide of 17 amino acids with antidepressant properties. This peptide, that we called spadin, can be conside…
-
3.
TREK-1 is the most studied background K<sub>2P</sub> channel. Its main role is to control cell excitability and maintain the membrane potential below the threshold of depolarization. TREK-1 is multi-regulated by a variety of physical and chemical stimuli which makes it a very promising and challenging target in the treatment of several pathologies. It is mainly expressed in the brain but also in heart, smooth muscle cells, endocrine pancreas, and prostate. In the nervous system, TREK-1 is involv…
Curated sources on file
2- 1.
-
2.
Note: Preclinical evidence only — no published human clinical trials. Cited paper describes in-vitro or animal-model mechanism.